{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:11:44Z","timestamp":1761415904532,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008810","name":"NSW Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002129","name":"Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.hlc.2022.06.691","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T19:30:18Z","timestamp":1661023818000},"page":"1531-1538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66)"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-4863","authenticated-orcid":false,"given":"Fang Shawn","family":"Foo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mildred","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina K.","family":"Poppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey C.","family":"Clare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin K.","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Webber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5914-6934","authenticated-orcid":false,"given":"Rod","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hlc.2022.06.691_bib1","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Ame","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.hlc.2022.06.691_bib2","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1093\/eurheartj\/ehab670","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hlc.2022.06.691_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hlc.2022.06.691_bib4","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.hlc.2022.06.691_bib5","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hlc.2022.06.691_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hlc.2022.06.691_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.hlc.2022.06.691_bib8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.hlc.2022.06.691_bib9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/eurjhf\/hfq154","article-title":"EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"12","author":"Maggioni","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.hlc.2022.06.691_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2015.12.046","article-title":"Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation","volume":"67","author":"Roth","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.hlc.2022.06.691_bib11","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.amjcard.2014.03.049","article-title":"Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008","volume":"113","author":"Schneider","year":"2014","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2022.06.691_bib12","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCHEARTFAILURE.109.912683","article-title":"Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF","volume":"3","author":"Heywood","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hlc.2022.06.691_bib13","unstructured":"Ministry of Health. National Minimum Dataset (Hospital Inpatient Events). Data Mart - Data Dictionary. Version 7.8. [Internet]. New Zealand; 2018 July 1 (cited 11 May 2021). Available from: https:\/\/www.health.govt.nz\/publication\/national-minimum-dataset-hospital-events-data-mart-data-dictionary."},{"issue":"1500","key":"10.1016\/j.hlc.2022.06.691_bib14","first-page":"40","article-title":"Completeness of ANZACS-QI Cardiac Implanted DEVICE Registry and agreement with national datasets: ANZACS-QI 30","volume":"132","author":"Foo","year":"2019","journal-title":"N\u00a0Z Med J"},{"issue":"1325","key":"10.1016\/j.hlc.2022.06.691_bib15","first-page":"41","article-title":"A\u00a0comparative analysis of cardiovascular disease risk profiles of five Pacific ethnic groups assessed in New Zealand primary care practice: PREDICT CVD-13","volume":"123","author":"Grey","year":"2010","journal-title":"N\u00a0Z Med J"},{"key":"10.1016\/j.hlc.2022.06.691_bib16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/heartjnl-2021-319853","article-title":"Contrasting trends in heart failure incidence in younger and older New Zealanders, 2006-2018","volume":"108","author":"Chan","year":"2022","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.hlc.2022.06.691_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"27","key":"10.1016\/j.hlc.2022.06.691_bib18","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2022.06.691_bib19","unstructured":"Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et\u00a0al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol. 2018l72(4):351\u2013366."},{"issue":"6","key":"10.1016\/j.hlc.2022.06.691_bib20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.hlc.2022.06.691_bib21","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"9704","key":"10.1016\/j.hlc.2022.06.691_bib22","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hlc.2022.06.691_bib23","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"MOCHA Investigators. Circulation"},{"issue":"23","key":"10.1016\/j.hlc.2022.06.691_bib24","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.hlc.2022.06.691_bib25","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/ejhf.1857","article-title":"Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hlc.2022.06.691_bib26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ahj.2004.04.006","article-title":"Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry","volume":"148","author":"Franciosa","year":"2004","journal-title":"Am Heart J"},{"issue":"9","key":"10.1016\/j.hlc.2022.06.691_bib27","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.hlc.2020.03.013","article-title":"Target doses of secondary prevention medications are not being achieved in patients with reduced left ventricular ejection fraction after acute coronary syndrome (ANZACS-QI 34)","volume":"29","author":"Chan","year":"2020","journal-title":"Heart Lung Circ"},{"issue":"11","key":"10.1016\/j.hlc.2022.06.691_bib28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jacc.2011.05.033","article-title":"Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study","volume":"58","author":"McNamara","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2022.06.691_bib29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.amjcard.2011.10.033","article-title":"How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with \u201cSCD-HeFT criteria?\u201d","volume":"109","author":"Zecchin","year":"2012","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.hlc.2022.06.691_bib30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamacardio.2016.2332","article-title":"Nurse-led titration of angiotensin-converting enzyme inhibitors, \u03b2-adrenergic blocking agents, and angiotensin receptor blockers in patients with heart failure with reduced ejection fraction","volume":"1","author":"Driscoll","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950622010022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950622010022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:06:40Z","timestamp":1761415600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950622010022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1443950622010022"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2022.06.691","relation":{},"ISSN":["1443-9506"],"issn-type":[{"type":"print","value":"1443-9506"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66)","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2022.06.691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}